Modules 1 is part 1 of 4-part course series on "Novel Approach to Treatment Resistant Depression".
Module 1: Disease Burden of Depression and Treatment Resistant Depression
- To pass this course and earn 1 CPD credit, doctors need to view a video and successfully complete a set of questions.
- This course is limited only to licensed psychiatrist.
- Duration of this course: approximately 30 minutes.
- Duration of total course series: 2 hours - 2 hours 30 minutes.
Module 2: Mechanism of Disease and the Innovative Role of Esketamine in Addressing Depression
- Describe the prevalence, natural history, and diagnosis of major depressive disorder and treatment-resistant depression
- Describe the challenges in achieving and maintaining remission in patients with treatment-resistant depression
- Describe the additional medical, disability, and mortality burden in patients with treatment-resistant depression
Module 3: Innovations in the Management of TRD
- Describe how the impairment of synaptic plasticity can lead to reduced synaptic connections in the brains of patients with major depressive disorder
- Describe the role of glutamate in maintaining synaptic connections and how alterations in glutamate signaling contribute to the development of major depressive disorder
- Describe the novel mechanism of action for esketamine and how this approach may be used to restore synaptic connections in the brains of patients with major depressive disorder
Module 4: Important Considerations in the Administration of Esketamine for TRD
- Describe the development of intranasal esketamine for treatment-resistant depression and major depression with suicidal ideation
- Describe the clinical evidence supporting the efficacy of intranasal esketamine for treatment-resistant depression
- Describe the clinical evidence supporting the safety of intranasal esketamine for treatment-resistant depression
Module 5: Clinical Case Studies
- Describe the novel design of esketamine nasal spray and the recommended instructions for administration in the treatment of depression
- Describe the most common adverse events due to esketamine use and the best approach to post-administration patient monitoring
- Describe the built-in precautions which promote the safe use of esketamine and mitigate the risk of abuse
- Apply clinical evidence regarding the efficacy and safety of esketamine to a spectrum of clinical scenarios involving patients with treatment-resistant depression
This CPD activity is done in collaboration with Johnson & Johnson Sdn Bhd.
Upon viewing the video and successfully completing the quiz in this module, you will be given 1 CPD point, that will be credited instantly in your MMA CPD account.To pass this module, get at least 9 out 11 questions correct.